On Wednesday, Diageo plc (ADR) (NYSE:DEO)’s shares inclined 0.59% to $118.03.
Diageo plc (ADR) (DEO) has once again ranked in the top 10 for Diversity MBA’s prestigious “50 Out Front Companies for Diversity Leadership” list of the best places in the country for women and diverse managers to work. This is the fourth successive year that Diversity MBA, a national leadership organization, has named Diageo to its list, and the third successive year that Diageo has ranked in the top 10.
For the 2015 list, Diversity MBA researched 600 companies to address the “who, what, when and how” of building inclusive diversity strategies that are aligned with talent administration. This builds on the existing analysis of the systems and methodologies for inclusive diversity and metrics that drive both results and impact conducted in previous years. The categories evaluated comprise: accountability, succession planning, representation, recruitment, workplace inclusion and retention, and board diversity. Diageo was specifically recognized as Top 10 Best in Class for succession planning and board diversity.
Diageo plc manufactures and distributes premium drinks. Its products comprise Scotch and Irish whiskey, gin, vodka, rum, and ready to drink products, in addition to beer and spirits, Irish cream liqueur, Raki, wine, tequila, Canadian and American whiskey, adult beverages, Cachaça, and finishing centre products.
Edwards Lifesciences Corp (NYSE:EW)’s shares gained 2.73% to $141.68.
Edwards Lifesciences Corp (EW) declared U.S. Food and Drug Administration (FDA) approval of its most advanced transcatheter aortic heart valve – the Edwards SAPIEN 3 valve with the Commander Delivery System – for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis.
Dr. Leon was the co-principal investigator for the PARTNER II Trial. SAPIEN 3 approval was based on a cohort of the PARTNER II Trial, which enrolled 583 high-risk patients at 29 U.S. sites.
The SAPIEN 3 valve builds on Edwards’ decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The new valve, accessible in 20mm, 23mm, 26mm and 29mm sizes, has an outer skirt – a cuff of fabric surrounding the valve frame – providing a seal to address paravalvular leak.
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves.
At the end of Wednesday’s trade, B2Gold Corp (NYSEMKT:BTG)‘s shares surged 1.86% to $1.64.
B2Gold Corp (BTG) disclosed robust results from the Optimized Feasibility Study (OFS) of Fekola Gold Project, commencement of construction at Fekola in Mali and the closing of the previously announced $350 million Revolving Credit Facility. All dollar figures are in United States dollars unless otherwise indicated. All Fekola Project amounts are on a 100% ownership basis.
Highlights of the Optimized Fekola Feasibility Study
- Open pit gold mine with an initial production life of mine (“LOM”) of 12.5 years based on probable mineral reserves
- Average annual gold production for years one through seven of 350,000 ounces per year at a $418 operating cash cost per ounce
- Average annual LOM gold production of 276,000 ounces per year at an operating cash cost of $552 per ounce
- New open pit probable mineral reserves of 49.2 million tonnes at a grade of 2.35 grams per tonne (“g/t”) gold containing 3.72 million ounces of gold at a stripping ratio of 4.5:1
- Average LOM gold recovery of 92.8% resulting in a total of 3.45 million ounces produced over the 12.5 year life of mine
B2Gold Corp., a mid-tier gold mining company, explores and develops mineral properties in Nicaragua, the Philippines, Namibia, Burkina Faso, and Chile. The company principally explores for gold, silver, and copper. It primarily holds a 100% interest in the La Libertad mine, which comprises of an exploitation concession covering 10,950 hectares located in Nicaragua; a 95% interest in the Limon mine property that covers an area of 12,000 hectares located northwest of Managua; and has 95% interest in Limon gold mine located in northwestern Nicaragua. The company also has interest in the Masbate mine, an open pit gold mine located near the northern tip of the island of Masbate; has a 90% interest in the Fekola gold mine located in southwestern Mali; and has 81% interest in the Kiaka gold project located in Burkina Faso. B2Gold Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Aetna Inc (NYSE:AET), ended its Wednesday’s trading session with -0.88% loss, and closed at $123.87.
A.M. Best has affirmed the various financial strength ratings (FSR) and the issuer credit ratings (ICR) for the insurance and health maintenance organization auxiliaries of Aetna Inc. (Aetna) (Hartford, CT) [NYSE:AET]. Conpresently, A.M. Best has affirmed the ICR of “bbb+” and debt ratings of Aetna. All ratings have a stable outlook.
The ratings affirmations for Aetna and its auxiliaries reflect the organization’s favorable long-term operating earnings and premium growth trend, excellent cash flows, its diversified product portfolio and improved financial flexibility at the parent level. The merged Aetna branded health and life insurance associates, led by Aetna Life Insurance Company, the organization’s flagship operating entity, have generated strong operating and net income results over several years. Aetna’s earnings have been driven by steady operating margins in its health care segment, which have been augmented by low medical cost trends and improved operational efficiencies. These trends were supported by solid operating margins in 2014. Recent growth in premium has been driven by membership growth in its health exchange, Medicare and Medicaid businesses. Aetna’s government business now represents over 40 percent of total health premiums. The company’s strong results were achieved despite one of the largest Medicare Advantage rate cuts in the program’s history.
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit administration services, dental, behavioral health, and vision plans on an insured basis, and an employer-funded or administrative basis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
